Melvin K. Spigelman - May 22, 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Melvin K. Spigelman
Stock symbol
ANTX
Transactions as of
May 22, 2025
Transactions value $
$0
Form type
4
Date filed
5/23/2025, 04:57 PM
Previous filing
Jun 21, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Spigelman Melvin K Director C/O AN2 THERAPEUTICS, INC., 1800 EL CAMINO REAL, SUITE D, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Melvin K. Spigelman 2025-05-23 0001339901

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (Right to Buy) Award $0 +19.1K $0.00 19.1K May 22, 2025 Common Stock 19.1K $1.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date.